Cellid Co. Ltd - Asset Resilience Ratio

Latest as of December 2025: 0.04%

Cellid Co. Ltd (299660) has an Asset Resilience Ratio of 0.04% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 299660 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩45.00 Million

≈ $30.50K USD Cash + Short-term Investments

Total Assets

₩110.87 Billion

≈ $75.13 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Cellid Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Cellid Co. Ltd.

Liquid Assets Composition Over Time

This chart breaks down Cellid Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 299660 long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩45.00 Million	0.04%
Total Liquid Assets	₩45.00 Million	0.04%

Asset Resilience Insights

Limited Liquidity: Cellid Co. Ltd maintains only 0.04% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Cellid Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Cellid Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Cellid Co. Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Cellid Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.04%	₩45.00 Million ≈ $30.50K	₩110.87 Billion ≈ $75.13 Million	-11.87pp
2024-12-31	11.91%	₩9.06 Billion ≈ $6.14 Million	₩76.09 Billion ≈ $51.56 Million	-11.59pp
2023-12-31	23.50%	₩15.02 Billion ≈ $10.18 Million	₩63.92 Billion ≈ $43.32 Million	-17.24pp
2022-12-31	40.74%	₩18.68 Billion ≈ $12.66 Million	₩45.86 Billion ≈ $31.08 Million	+6.52pp
2021-12-31	34.23%	₩19.94 Billion ≈ $13.51 Million	₩58.26 Billion ≈ $39.48 Million	+9.79pp
2020-12-31	24.43%	₩12.07 Billion ≈ $8.18 Million	₩49.40 Billion ≈ $33.48 Million	+21.38pp
2019-12-31	3.05%	₩1.60 Billion ≈ $1.08 Million	₩52.52 Billion ≈ $35.59 Million	-52.42pp
2018-12-31	55.47%	₩7.89 Billion ≈ $5.34 Million	₩14.22 Billion ≈ $9.63 Million	-35.40pp
2017-12-31	90.86%	₩4.51 Billion ≈ $3.06 Million	₩4.96 Billion ≈ $3.36 Million	+4.43pp
2016-12-31	86.44%	₩3.29 Billion ≈ $2.23 Million	₩3.81 Billion ≈ $2.58 Million	--

pp = percentage points

About Cellid Co. Ltd

KQ:299660 Korea Biotechnology

Market Cap

$46.19 Million

₩68.15 Billion KRW

Market Cap Rank

#22280 Global

#1413 in Korea

Share Price

₩2310.00

Change (1 day)

+1.32%

52-Week Range

₩1025.00 - ₩4110.00

All Time High

₩127128.20